Abstracts Archive - Page 1728 of 2607 - ACR Meeting Abstracts

Abstract Number: 1934 • 2016 ACR/ARHP Annual Meeting
Cutaneous Manifestations of ANCA-Associated Vasculitis
Zelma ChiesaFuxench¹, Robert Micheletti², Raashid Luqmani³, Richard Watts⁴, Anthea Craven⁵ and Peter A. Merkel⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ³Oxford, Oxford, United Kingdom, ⁴Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁵Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
The cutaneous manifestations of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), are varied…
Abstract Number: 1935 • 2016 ACR/ARHP Annual Meeting
Hypertrophic Pachymeningitis in a Population with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Study in a Single Japanese Institution
Yasuhiro Shimojima, Dai Kishida, Akiyo Hineno, Masahide Yazaki, Yoshiki Sekijima and Shu-ichi Ikeda, Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Hypertrophic pachymeningitis (HP) is an inflammatory disorder causing focal and diffuse thickening of the dura mater. It is realized that anti-neutrophil cytoplasmic antibody (ANCA)-associated…
Abstract Number: 1936 • 2016 ACR/ARHP Annual Meeting
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study
Patompong Ungprasert¹, Cynthia S. Crowson², Rodrigo Cartin-Ceba³, James A. Garrity⁴, Wendy M. Smith⁵, Ulrich Specks⁶, Eric L. Matteson¹ and Ashima Makol⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Ophthalmology, Mayo Clinic, Rochester, MN, ⁵Department of Ophthalmology, Mayo Clinic, Rochester, MN, ⁶Mayo Clinic, Rochester, MN, ⁷Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is…
Abstract Number: 1937 • 2016 ACR/ARHP Annual Meeting
Analysis of Innate and Adaptive Immune Responses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
Jeremie Dion^1,2, Jonathan London^2,3, Benjamin Chaigne^2,4, Nicolas Dumoitier², Bertrand Dunogué⁵, Pascal Cohen³, Matthieu Groh⁴, Claire Le Jeunne⁴, Luc Mouthon^2,5 and Benjamin Terrier^2,5, ¹Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ³Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁵Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA, formerly called Churg-Strauss syndrome) belongs to ANCA-associated vasculitis and is characterized by late onset asthma, blood and tissue eosinophilia…
Abstract Number: 1938 • 2016 ACR/ARHP Annual Meeting
Bronchiectasis Are Highly Prevalent in Anti-MPO ANCA-Associated Vasculitis and Associate with a Distinct Disease Phenotype
Antoine Néel¹, Alexandra Espitia¹, Pierre Paul Arrigoni², Christelle Volteau³, Agathe Masseau¹, Marie Rimbert⁴, Christian Agard¹, Fadi Fakhouri⁵, Renan Liberge² and Mohamed Hamidou⁶, ¹Internal Medicine Department, Nantes University Hospital, Nantes, France, ²Radiology Department, Nantes University Hospital, Nantes, France, ³Clinical Research Department, Nantes University Hospital, Nantes, France, ⁴Immunology Laboratory, Nantes University Hospital, Nantes, France, ⁵Nephrology Department, Nantes University Hospital, Nantes, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France
Background/Purpose: To assess the prevalence of bronchiectasis in a western cohort of ANCA positive GPA or MPA and its correlations with disease phenotype and outcome.…
Abstract Number: 1939 • 2016 ACR/ARHP Annual Meeting
Immunologic, Clinical and Demographic Correlates in 51 Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Grant Hughes¹ and Meredith Barnes², ¹University of Washington, Seattle, WA, ²Medicine, University of Washington, Seattle, WA
Background/Purpose: Exposure to illicit cocaine and its frequent adulterant, levamisole, is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of…
Abstract Number: 1940 • 2016 ACR/ARHP Annual Meeting
High Prevalence of Inflammatory Heart Disease in Eosinophillic Granulomatosis with Polyangiitis (Churg Strauss) Patients
Eloi Garcia Vives¹, Len Harty² and David Jayne³, ¹Vall d'Hebrón Hospital, Barcelona, Spain, ²Vasculitis & Lupus, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ³Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom
Background/Purpose: To establish EGPA/Churg Strauss inflammatory heart disease prevalence and develop an algorithm for heart disease screening in EGPA patients. Methods: An audit of all…
Abstract Number: 1941 • 2016 ACR/ARHP Annual Meeting
Retrospective Survey of Concomitant Autoimmune Diseases and Autoantibodies in a Cohort of Patients with ANCA-Associated Vasculitis (AAV)
Marta Casal Moura^1,2, Sergio Prieto-González², Georgina Espígol-Frigolé², Giuseppe Murgia^2,3, Marco Alba², Jose Hernández-Rodríguez² and Maria C. Cid², ¹Department of Internal Medicine, São João Hospital Center, Porto, Portugal, ²Hospital Clínic. University of Barcelona. IDIBAPS, Vasculitis Research Unit. Department of Autoimmune Diseases, Spain, Barcelona, Spain, ³University Clinic for Visceral Surgery and Medicine Bauchzentrum Bern, Bern, Switzerland
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) - granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) have heterogenous clinic…
Abstract Number: 1942 • 2016 ACR/ARHP Annual Meeting
Presentation and Clinical Features of ANCA-Associated Vasculitis in US African Americans: Experience from a Single Center
Sebastian Sattui¹, Andrew Westfall² and Angelo L. Gaffo³, ¹Tinsley Harrison Internal Medicine Residency Program, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, Birmingham VA Medical Center, Birmingham, AL
Title: Presentation and Clinical Features of ANCA-associated Vasculitis in US African Americans: Experience From a Single Center Background/Purpose: Little is known about the presentation,…
Abstract Number: 1943 • 2016 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse
Maxime Samson¹, Hervé Devilliers², Xavier Puéchal³, Christian Pagnoux⁴, Pascal Cohen³, Luc Mouthon³, Benjamin Terrier⁵ and Loïc Guillevin³, ¹Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: To identify associations between patients’ clinical and biological characteristics at diagnosis of antineutrophil cytoplasmic antibody-associated vasculitides (AAVs), and their relapse during follow-up. Methods: Long-term…
Abstract Number: 1944 • 2016 ACR/ARHP Annual Meeting
Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis
Zachary Wallace¹, Eli Miloslavsky², Sebastian H. Unizony³, Na Lu⁴, Gary S. Hoffman⁵, Cees G.M. Kallenberg⁶, Carol A. Langford⁷, Peter A. Merkel⁸, Paul A. Monach⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene William St.Clair¹², Paul Bruntetta¹³, Matthew Cascino¹⁴, Hyon K. Choi¹⁵ and John H. Stone³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Hospital for Special Surgery, Cornell, New York, NY, ¹²Rheumatology and Immunology, Duke University, Durham, NC, ¹³Genentech, Inc., South San Francisco, CA, ¹⁴University of California-San Francisco, San Francisco, CA, ¹⁵Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) treatment includes high dose glucocorticoids (GCs), which are associated with increased body-mass index (BMI), a complication abhorred by patients and associated…
Abstract Number: 1945 • 2016 ACR/ARHP Annual Meeting
Development and Validation of Case-Finding Algorithms for the Identification of Patients with ANCA-Associated Vasculitis and Large-Vessel Vasculitis in Healthcare Administrative Databases
Antoine G. Sreih¹, Narender Annapureddy², Jason Springer³, Kevin Byram⁴, George Casey⁵, Andy Cruz⁶, Maya Estephan⁷, Vince Frangiosa⁸, Michael D. George⁸, Mei Liu⁹, Mehrdad Maz¹⁰, Adam Parker⁷, Sapna Sangani¹¹, Rebecca Sharim¹² and Peter A. Merkel¹³, ¹Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Vanderbilt University, Nashville, TN, ³Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS, ⁴Internal Medicine, Vanderbilt University, Nashville, TN, ⁵The Vasculitis Foundation, Kansas City, MO, ⁶Informational Technology, The University of Pennsylvania, Philadelphia, PA, ⁷Rheumatology, The University of Kansas, Kansas City, KS, ⁸Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Informational Technology, The University of Kansas, Kansas City, KS, ¹⁰Allergy, Clinical Immunology, and Rheumatology, The University of Kansas Medical Center, Department of Internal Medicine, Division of Allergy, Clinical Immunology and Rheumatology, Kansas City, KS, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Temple University, Philadelphia, PA, ¹³Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of vasculitides that consists of granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA), and microscopic polyangiitis…
Abstract Number: 1946 • 2016 ACR/ARHP Annual Meeting
Antineutrophil Cytoplasmic Antibody (ANCA) Type and Body Mass Index in ANCA-Associated Vasculitis (AAV)
Zachary Wallace¹, Na Lu², Eli Miloslavsky³, Ulrich Specks⁴, Gary S. Hoffman⁵, Cees G.M. Kallenberg⁶, Carol A. Langford⁷, Peter A. Merkel⁸, Paul A. Monach⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene William St.Clair¹², Paul Bruntetta¹³, Hyon K. Choi¹⁴ and John H. Stone¹⁵, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Hospital for Special Surgery, Cornell, New York, NY, ¹²Rheumatology and Immunology, Duke University, Durham, NC, ¹³Genentech, Inc., South San Francisco, CA, ¹⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ¹⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Antineutrophil Cytoplasmic Antibody (ANCA) Type and Body Mass Index in ANCA-Associated Vasculitis (AAV) Background/Purpose: Phenotypic, genetic, and treatment differences distinguish PR3- and MPO-ANCA+ ANCA-associated vasculitis…
Abstract Number: 1947 • 2016 ACR/ARHP Annual Meeting
Ocular Manifestations of ANCA-Associated Vasculitis
Sophie Cai^1,2, George Papaliodis^2,3, Leo Lu⁴, Hyon K. Choi⁵, Ulrich Specks⁶, Peter A. Merkel⁷, Philip Seo⁸, Robert F. Spiera⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees G.M. Kallenberg¹², William St Clair¹³, Nadia Tchao¹⁴, Fernando Fervenza⁶, Paul A. Monach¹⁵, W Joseph McCune¹⁶, John H. Stone¹⁷, Eli Miloslavsky¹⁸ and RAVE-ITN and WGET Research Groups, ¹Ophthalmology, Johns Hopkins Wilmer Eye Institute, Baltimore, MD, ²Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Uveitis and Immunology, Massachusetts Eye and Ear, Boston, MA, ⁴Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Mayo Clinic, Rochester, MN, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁸Medicine, Johns Hopkins University, Baltimore, MD, ⁹Hospital for Special Surgery, Cornell, New York, NY, ¹⁰Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatology, Cleveland Clinic, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹³Rheumatology, Duke University Medical Center, Durham, NC, ¹⁴Immune Tolerance Network, San Francisco, CA, ¹⁵Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁶Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ¹⁷Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹⁸Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Ocular involvement in ANCA-associated vasculitis (AAV) can cause substantial morbidity. We aimed to characterize patterns of ocular involvement in AAV and their response to…
Abstract Number: 1948 • 2016 ACR/ARHP Annual Meeting
Evaluation of Body Composition Parameters in Granulomatosis with Polyangiitis: Association of Fat Mass Parameters with Disease Activity and Inflammatory Markers
Mariana O Perez¹, Valeria F Caparbo², Mauricio Levy-Neto² and Rosa M R Pereira², ¹Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Granulomatosis with polyangiitis (GPA, Wegener´s) patients are more exposed to traditional cardiovascular risk factor, including obesity. In rheumatic diseases, inflammation has been associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].